|
Malignant neoplasm of prostate
|
0.390 |
AlteredExpression
|
disease |
BEFREE |
Here we show that similar to EAF2, EAF1 is frequently down-regulated in advanced prostate cancer.
|
31229879 |
2019 |
|
Malignant neoplasm of prostate
|
0.390 |
AlteredExpression
|
disease |
BEFREE |
Furthermore, immunostaining of p-STAT3 was increased in human prostate cancer specimens with EAF2 downregulation and/or p53 nuclear staining.
|
29518696 |
2018 |
|
Malignant neoplasm of prostate
|
0.390 |
Biomarker
|
disease |
BEFREE |
Here we show that knockdown of EAF2 or its homolog EAF1 sensitized prostate cancer cells to DNA damage and the sensitization did not require p53.
|
27721405 |
2017 |
|
Malignant neoplasm of prostate
|
0.390 |
Biomarker
|
disease |
BEFREE |
Concurrent knockdown of p53 and EAF2 induced an increase in proliferation and migration in cultured prostate cancer cells, and conventional p53 and EAF2 knockout mice developed prostate cancer.
|
29029019 |
2017 |
|
Malignant neoplasm of prostate
|
0.390 |
Biomarker
|
disease |
BEFREE |
The effect of EAF2 and/or FOXA1 knockdown on LNCaP human prostate cancer cell proliferation and migration was tested using BrdU assay and transwell migration assay.
|
25808853 |
2015 |
|
Malignant neoplasm of prostate
|
0.390 |
Biomarker
|
disease |
BEFREE |
The tumor suppressor EAF2 is regulated by androgen signaling and associated with prostate cancer.
|
24727455 |
2014 |
|
Malignant neoplasm of prostate
|
0.390 |
Biomarker
|
disease |
BEFREE |
ELL-associated factor 2 (EAF2) is an androgen-responsive tumor suppressor frequently deleted in advanced prostate cancer that functions as a transcription elongation factor of RNA Pol II through interaction with the ELL family proteins.
|
24260246 |
2013 |
|
Malignant neoplasm of prostate
|
0.390 |
Biomarker
|
disease |
CTD_human |
Inhibition of 5alpha-reductase enhances testosterone-induced expression of U19/Eaf2 tumor suppressor during the regrowth of LNCaP xenograft tumor in nude mice.
|
20564326 |
2010 |
|
Malignant neoplasm of prostate
|
0.390 |
AlteredExpression
|
disease |
BEFREE |
U19/Eaf2 is an androgen-response gene and its downregulation is frequently observed in advanced human prostate cancer.
|
17044034 |
2007 |
|
Malignant neoplasm of prostate
|
0.390 |
Biomarker
|
disease |
BEFREE |
These findings suggest that ELL-U19/Eaf2 interaction is potentially important in prostate cancer progression and/or acute myeloid leukemia.
|
16114057 |
2006 |
|
Prostatic Neoplasms
|
0.350 |
Biomarker
|
group |
BEFREE |
ELL-associated factor 1 is a transcription elongation factor that shares significant homology and functional similarity to the androgen-responsive prostate tumor suppressor ELL-associated factor 2.
|
31229879 |
2019 |
|
Prostatic Neoplasms
|
0.350 |
Biomarker
|
group |
BEFREE |
Elongation factor, RNA polymerase II, 2 (ELL2) is an RNA Pol II elongation factor with functional properties similar to ELL that can interact with the prostate tumor suppressor EAF2.
|
28870994 |
2017 |
|
Prostatic Neoplasms
|
0.350 |
PosttranslationalModification
|
group |
BEFREE |
These findings suggest that EAF2 and p53 functionally interact in prostate tumor suppression and that simultaneous inactivation of EAF2 and p53 can drive prostate carcinogenesis.
|
29029019 |
2017 |
|
Prostatic Neoplasms
|
0.350 |
Biomarker
|
group |
BEFREE |
These results suggest that the EAF2 knockout mouse on the C57BL/6J and FVB/NJ genetic backgrounds provides a model of PIN lesions associated with an altered prostate microvasculature and reactive stromal compartment corresponding to that reported in human prostate tumors.
|
24260246 |
2013 |
|
Prostatic Neoplasms
|
0.350 |
Biomarker
|
group |
CTD_human |
Inhibition of 5alpha-reductase enhances testosterone-induced expression of U19/Eaf2 tumor suppressor during the regrowth of LNCaP xenograft tumor in nude mice.
|
20564326 |
2010 |
|
Prostatic Neoplasms
|
0.350 |
AlteredExpression
|
group |
LHGDN |
Suppression of prostate tumor growth by U19, a novel testosterone-regulated apoptosis inducer.
|
12907652 |
2003 |
|
Lung Neoplasms
|
0.300 |
Biomarker
|
group |
CTD_human |
Inhibition of 5alpha-reductase enhances testosterone-induced expression of U19/Eaf2 tumor suppressor during the regrowth of LNCaP xenograft tumor in nude mice.
|
20564326 |
2010 |
|
B-Cell Lymphomas
|
0.300 |
Biomarker
|
group |
CTD_human |
Inhibition of 5alpha-reductase enhances testosterone-induced expression of U19/Eaf2 tumor suppressor during the regrowth of LNCaP xenograft tumor in nude mice.
|
20564326 |
2010 |
|
Malignant neoplasm of lung
|
0.300 |
Biomarker
|
disease |
CTD_human |
Inhibition of 5alpha-reductase enhances testosterone-induced expression of U19/Eaf2 tumor suppressor during the regrowth of LNCaP xenograft tumor in nude mice.
|
20564326 |
2010 |
|
Liver carcinoma
|
0.300 |
Biomarker
|
disease |
CTD_human |
Inhibition of 5alpha-reductase enhances testosterone-induced expression of U19/Eaf2 tumor suppressor during the regrowth of LNCaP xenograft tumor in nude mice.
|
20564326 |
2010 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Elongation factor for RNA polymerase 2 (ELL2) and ELL associated factor 2 (EAF2) have been reported to have tumor suppressive properties in prostate epithelial cells.
|
30009504 |
2018 |
|
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
The tumor suppressor genes EAF2 and p53 are frequently dysregulated in prostate cancers.
|
29518696 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
ELL-associated factor 2 (EAF2) is an androgen-regulated tumor suppressor and its intracellular localization can be modulated by ultraviolet light, suggesting a potential role for EAF2 in androgen regulation of DNA repair in prostate cancer cells.
|
27721405 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
ELL-associated factor 2 (EAF2) is a tumor suppressor that is frequently downregulated in advanced prostate cancer.
|
29029019 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Identification of factors capable of modulating EAF2 function will help elucidate the mechanisms underlying EAF2 tumor suppressive function.
|
25808853 |
2015 |